Utilization of next generation sequencing in ovarian and endometrial cancers at a single institution

Abstract

Objective: An increasing number of targeted therapies have been approved by the FDA for gynecologic malignancies. The expanded availability of affordable next-generation sequencing has allowed for widespread tumor testing for pathogenic mutations. We sought to describe the most frequent genetic mutations associated with common histologic subtypes of a selected cohort of ovarian and endometrial cancer patients at a single large academic medical center.